Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Stock Has Average Price Target of $55.40 According to Analysts

Shares of Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) have earned a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $55.40.

Separately, Oppenheimer decreased their target price on shares of Pelthos Therapeutics from $66.00 to $64.00 and set an “outperform” rating on the stock in a report on Friday, August 14th.

Pelthos Therapeutics Stock Performance

Shares of PTHS opened at $22.19 on Wednesday. The company has a debt-to-equity ratio of 3.40, a quick ratio of 1.31 and a current ratio of 1.98. The stock has a market capitalization of $84.99 million, a price-to-earnings ratio of -1.01 and a beta of 3.01. Pelthos Therapeutics has a 52-week low of $18.19 and a 52-week high of $37.50. The stock’s 50-day simple moving average is $25.49 and its 200 day simple moving average is $25.34.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($6.62) earnings per share for the quarter. Pelthos Therapeutics had a negative net margin of 165.24% and a negative return on equity of 204.71%. The company had revenue of $15.60 million for the quarter. Research analysts forecast that Pelthos Therapeutics will post -15.22 EPS for the current fiscal year.

Institutional Investors Weigh In On Pelthos Therapeutics

A hedge fund recently raised its stake in Pelthos Therapeutics stock. Knott David M Jr raised its holdings in Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) by 9.3% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 21,073 shares of the company’s stock after acquiring an additional 1,792 shares during the period. Knott David M Jr owned approximately 0.63% of Pelthos Therapeutics worth $443,000 at the end of the most recent reporting period. Institutional investors own 77.96% of the company’s stock.

About Pelthos Therapeutics

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).